Association With Low Compliance Bladder in Women With LUTS
Comparisons of Clinical and Urodynamic Parameters and Persistence in the Treatment for Women With Different Types of Low Bladder Compliance
Hypothesis / aims of study The clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate. Thus, this study aimed to elucidate the above association.
Study design, materials and methods Between January 1996 and December 2021, the medical records of all consecutive women who underwent urodynamic studies for their lower urinary tract symptoms were reviewed to elucidate the clinical significance of low bladder compliance.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ho-Hsiung Lin, MD, PhD
- Phone Number: 71557 +886-2-23123456
- Email: hhlin@ntuh.gov.tw
Study Locations
-
-
-
Taipei, Taiwan, 100
- Department of Obstetrics and Gynecology, National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Urodynamic finding with low bladder compliance
Exclusion Criteria:
- Nil.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Low compliance
Low urinary tract symptoms with low bladder compliance
|
The clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate.
Thus, this study aimed to elucidate the above association.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bladder capacity (mL)
Time Frame: 1996/1/1~2021/12/31
|
To compare the bladder capacity (mL) between the groups with and without low bladder compliance.
The bladder capacity will be derived from the filling cystometry of urodynamic studies.
|
1996/1/1~2021/12/31
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Persistence rates of treatment (%)
Time Frame: 1996/1/1~2021/12/31
|
To compare the persistence rates of treatment (%) between the groups with and without low bladder compliance.
The persistent rate of treatment will be checked from outpatient medical records about prescription.
|
1996/1/1~2021/12/31
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ho-Hsiung Lin, MD, PhD, Department of Obstetrics and Gynecology, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Pathological Conditions, Anatomical
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urination Disorders
- Lower Urinary Tract Symptoms
- Urological Manifestations
- Urinary Bladder Diseases
- Urethral Diseases
- Urethral Obstruction
- Urinary Incontinence
- Urinary Bladder, Overactive
- Prolapse
- Pelvic Organ Prolapse
- Urinary Bladder Neck Obstruction
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Muscarinic Antagonists
Other Study ID Numbers
Other Study ID Numbers
- 202303086RINC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Bladder, Overactive
-
NCT01500382TerminatedOveractive Bladder | Overactive Urinary Bladder
-
NCT04197466CompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder Syndrome
-
NCT02138747Completed
-
NCT00909428CompletedOveractive Bladder Syndrome
-
NCT02946723Unknown
-
NCT00628615UnknownLower Urinary Tract Symptoms | Overactive Bladder Syndrome
-
NCT04389307CompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder Training
Clinical Trials on medical treatment for lower urinary tract symptoms
-
NCT03394651UnknownLower Urinary Tract Symptoms
-
NCT02038699WithdrawnAdvanced Colorectal Cancer | Advanced Glioblastoma | Advanced Triple-negative Breast Cancer | Advanced Non-small Cell Lung Cancer
-
NCT05609695Not yet recruitingImmune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
-
NCT02030340Unknown
-
NCT07012941Not yet recruitingUreterolithiasis | Renal Calculi
-
NCT03541954TerminatedChronic Pelvic Pain | Chronic Perineal Pain
-
NCT04722458CompletedLower Urinary Tract Symptoms | Urinary Incontinence
-
NCT00386997Terminated
-
NCT04871984Not yet recruitingRenal Stone | Ureteral Stone
-
NCT07077447RecruitingUpper Urinary Tract Urothelial Carcinoma